Biodesix Statistics
Total Valuation
Biodesix has a market cap or net worth of $253.12 million. The enterprise value is $294.92 million.
| Market Cap | 253.12M |
| Enterprise Value | 294.92M |
Important Dates
The last earnings date was Wednesday, August 5, 2026, after market close.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biodesix has 10.55 million shares outstanding. The number of shares has increased by 21.27% in one year.
| Current Share Class | 10.55M |
| Shares Outstanding | 10.55M |
| Shares Change (YoY) | +21.27% |
| Shares Change (QoQ) | +6.63% |
| Owned by Insiders (%) | 40.45% |
| Owned by Institutions (%) | 28.99% |
| Float | 5.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.45 |
| Forward PS | 2.07 |
| PB Ratio | 27.45 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.85 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.85, with a Debt / Equity ratio of 7.85.
| Current Ratio | 2.85 |
| Quick Ratio | 2.56 |
| Debt / Equity | 7.85 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.55 |
Financial Efficiency
Return on equity (ROE) is -540.01% and return on invested capital (ROIC) is -16.68%.
| Return on Equity (ROE) | -540.01% |
| Return on Assets (ROA) | -14.05% |
| Return on Invested Capital (ROIC) | -16.68% |
| Return on Capital Employed (ROCE) | -25.75% |
| Weighted Average Cost of Capital (WACC) | 7.69% |
| Revenue Per Employee | $308,201 |
| Profits Per Employee | -$83,120 |
| Employee Count | 334 |
| Asset Turnover | 1.12 |
| Inventory Turnover | 12.86 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +211.34% in the last 52 weeks. The beta is 0.56, so Biodesix's price volatility has been lower than the market average.
| Beta (5Y) | 0.56 |
| 52-Week Price Change | +211.34% |
| 50-Day Moving Average | 20.36 |
| 200-Day Moving Average | 13.57 |
| Relative Strength Index (RSI) | 60.57 |
| Average Volume (20 Days) | 76,204 |
Short Selling Information
The latest short interest is 157,187, so 1.49% of the outstanding shares have been sold short.
| Short Interest | 157,187 |
| Short Previous Month | 167,970 |
| Short % of Shares Out | 1.49% |
| Short % of Float | 3.13% |
| Short Ratio (days to cover) | 2.25 |
Income Statement
In the last 12 months, Biodesix had revenue of $102.94 million and -$27.76 million in losses. Loss per share was -$3.13.
| Revenue | 102.94M |
| Gross Profit | 84.93M |
| Operating Income | -20.58M |
| Pretax Income | -27.76M |
| Net Income | -27.76M |
| EBITDA | -15.03M |
| EBIT | -20.61M |
| Loss Per Share | -$3.13 |
Balance Sheet
The company has $30.00 million in cash and $71.80 million in debt, with a net cash position of -$41.80 million or -$3.96 per share.
| Cash & Cash Equivalents | 30.00M |
| Total Debt | 71.80M |
| Net Cash | -41.80M |
| Net Cash Per Share | -$3.96 |
| Equity (Book Value) | 9.14M |
| Book Value Per Share | 0.87 |
| Working Capital | 28.27M |
Cash Flow
In the last 12 months, operating cash flow was -$19.83 million and capital expenditures -$412,000, giving a free cash flow of -$20.24 million.
| Operating Cash Flow | -19.83M |
| Capital Expenditures | -412,000 |
| Depreciation & Amortization | 5.58M |
| Net Borrowing | -15,000 |
| Free Cash Flow | -20.24M |
| FCF Per Share | -$1.92 |
Margins
Gross margin is 82.50%, with operating and profit margins of -19.99% and -26.97%.
| Gross Margin | 82.50% |
| Operating Margin | -19.99% |
| Pretax Margin | -26.97% |
| Profit Margin | -26.97% |
| EBITDA Margin | -14.60% |
| EBIT Margin | -20.02% |
| FCF Margin | n/a |
Dividends & Yields
Biodesix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.27% |
| Shareholder Yield | -21.27% |
| Earnings Yield | -11.02% |
| FCF Yield | -8.03% |
Analyst Forecast
The average price target for Biodesix is $34.00, which is 41.73% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $34.00 |
| Price Target Difference | 41.73% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 20.85% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 15, 2025. It was a reverse split with a ratio of 1:20.
| Last Split Date | Sep 15, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
Biodesix has an Altman Z-Score of -6.16 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.16 |
| Piotroski F-Score | 4 |